WilmerHale Represents Summit Therapeutics in $25M Private Placement

Download IconDownload Print IconPrint

WilmerHale Represents Summit Therapeutics in $25M Private Placement

Client News

Related Solutions

Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.
Leveraging our sophisticated technical, market and legal experience to help clients effectively and efficiently manage complex transactions and get the deal done.
WilmerHale represented Summit Therapeutics plc—a biopharmaceutical company focused on the discovery, development and commercialization of new mechanism antibiotics—in a private placement of 15,625,000 of its American Depositary Shares to the investor, Robert W. Duggan. Summit received $25 million in aggregate gross proceeds from the private placement, before expenses. The transaction signed on December 14, 2018 and closed on January 9, 2019, following the approval of Summit’s shareholders.

The WilmerHale team representing Summit consisted of Brian Johnson, Scott Lunin and Chip McCorkle.

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel